Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $18.75.
Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings downgraded shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday.
Read Our Latest Analysis on Lexeo Therapeutics
Lexeo Therapeutics Price Performance
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, analysts expect that Lexeo Therapeutics will post -1.23 EPS for the current fiscal year.
Insider Buying and Selling
In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,644 shares of company stock valued at $336,462 over the last ninety days. Insiders own 2.00% of the company’s stock.
Institutional Trading of Lexeo Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC grew its position in Lexeo Therapeutics by 57.8% in the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after acquiring an additional 1,850,211 shares in the last quarter. RA Capital Management L.P. bought a new stake in Lexeo Therapeutics in the fourth quarter worth approximately $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in Lexeo Therapeutics in the fourth quarter worth approximately $47,299,000. Vestal Point Capital LP grew its position in Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,225,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Lexeo Therapeutics in the second quarter worth approximately $16,117,000. 60.67% of the stock is owned by institutional investors.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Featured Stories
- Five stocks we like better than Lexeo Therapeutics
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
